Costs of epilepsy in an intermediate care facility for persons with mental retardation.
Epilepsy is a significant comorbid condition in institutionalized persons with developmental disabilities and may contribute significant additional costs. This study was conducted to provide an estimate of the costs of epilepsy from the institutional perspective. Costs were measured retrospectively for 50 persons with epilepsy and 50 persons without epilepsy matched by severity of developmental disability. A time and motion study was employed to assign opportunity costs to documented nursing and physician activities. Two separate methods of attribution were used and incremental costs attributable to epilepsy were found to be approximately $825 and $918 per person over a 6-month period. The following categories accounted for costs: personnel (47.0%), drug (39.6%), hospitalization (9.4%), and laboratories/procedures (4.0%). Results are useful for describing the economic burden of epilepsy.
Burke
T A
TA
Ohio State University, USA.
McKee
J R
JR
Pathak
D S
DS
Donahue
R M
RM
Parasuraman
T V
TV
Batenhorst
A S
AS
D000328:Adult; D000927:Anticonvulsants / Q000191:economics; D004569:Electroencephalography / Q000191:economics; D004827:Epilepsy / Q000150:complications* / Q000188:drug therapy / Q000191:economics* / Q000451:nursing; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data; D006760:Hospitalization / Q000191:economics; D006801:Humans; D008607:Intellectual Disability / Q000150:complications* / Q000191:economics; D007380:Intermediate Care Facilities / Q000191:economics*; D008297:Male; D009726:Nurses / Q000191:economics; D010820:Physicians / Q000191:economics; D012044:Regression Analysis; D012189:Retrospective Studies; D013996:Time and Motion Studies; D014481:United States
D000927:Anticonvulsants